TDACU NASDAQ
Translational Development Acquisition Corp.
1W: +8.8%
1M: +4.8%
3M: +20.4%
YTD: +20.4%
1Y: +22.2%
$12.57
+1.02 (+8.83%)
Pre-Market: $13.36 (+0.79, +6.28%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$288.2M
52W Range10.31-17.29
Volume940
Avg Volume830
Beta0.27
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMichael Hoffman
Employees2
SectorFinancial Services
IndustryShell Companies
IPO Date2024-12-23
77 Water Street
New York City, NY 10006
US
New York City, NY 10006
US
646 229 7549
About Translational Development Acquisition Corp.
Translational Development Acquisition Corp. (TDACU) functions as a blank check entity, currently lacking any operational businesses or ventures of its own. Its sole purpose is to identify and complete a significant business combination, which could take the form of a merger, acquisition, asset purchase, share exchange, recapitalization, or other similar transaction with an existing company or companies. TDACU's strategic focus for this combination is specifically directed towards enterprises engaged in the oil, gas, or broader natural resources industries located within Eastern Europe.
Latest News
ProLogium and Translational Development Acquisition Corp. Announce $50 Million Committed Primary Capital Investment to Support Proposed Business Combination
Translational Development Acquisition (NASDAQ:TDACU) Stock Price Down 0.2% – What’s Next?
Trident Acquisitions (OTCMKTS:TDACU) Stock Price Down 0.2% – Here’s Why
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Jarratt Christopher | 0 | — | 2024-12-20 | |
| Keith Curtis T | 0 | — | 2024-12-20 | |
| TDAC Partners LLC | 4,657,500 | — | 2024-12-20 | |
| Reddy E Premkumar | 0 | — | 2024-12-20 | |
| Kestenbaum Matthew | 0 | — | 2024-12-20 |